您的位置: 首页 > 农业专利 > 详情页

PARTICULES DE TYPE VIRAL À BASE D'ÉPITOPE PALIVIZUMAB
专利权人:
INC.;VLP BIOTECH, INC.;MEDIMMUNE, LLC;VLP BIOTECH
发明人:
MILICH, DAVID, R.,WHITACRE, DAVID, C.,SCHICKLI, JEANNE, H.
申请号:
EP14765099
公开号:
EP2968518A4
申请日:
2014.03.14
申请国别(地区):
EP
年份:
2016
代理人:
摘要:
The present disclosure generally relates to immunogens for eliciting an antibody response against respiratory syncytial virus (RSV). More specifically, the present disclosure relates to virus-like particles (VLPs) including a RSV F protein epitope, as well as methods of use thereof. Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in infants and young children (Hall et al., NEJM, 360:5888-598, 2009; and Nair et al., Lancet, 375:1545-1555, 2010) and a vaccine to protect this young population is of high priority.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充